Emerging Signal Regulating Potential of Genistein Against Alzheimer’s Disease: A Promising Molecule of Interest
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive, irreversible brain disorder characterized by pathological aggregation of the amyloid-β peptide (Aβ) and tau protein; both of these are toxic to neurons. Currently, natural products are regarded as an alternative approach to discover novel multipotent drugs against AD. Dietary soy isoflavone genistein is one of the examples of such agents that occurs naturally and is known to exert a number of beneficial health effects. It has been observed that genistein has the capacity to improve the impairments triggered by Aβ and also it possesses the antioxidant potential to scavenge the AD-mediated generation of free radicals. Furthermore, genistein can interact directly with the targeted signaling proteins and also can stabilize their activity to combat AD. In order to advance the development of AD treatment, a better comprehension of the direct interactions of target proteins and genistein might prove beneficial. Therefore, this article focuses on the therapeutic effects and molecular targets of genistein, which has been found to target directly the Aβ and tau to control the intracellular signaling pathways responsible for neurons death in the AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“In case of autosomal dominant forms of early onset AD, mutations in APP, presenilin-1 (PSEN1) or presenilin-2 (PSEN2) are accountable (Campion et al., 1999; Żekanowski et al., 2003; Uddin et al., 2016c).”
BackgroundMitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology
Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A., & Perry, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.006 · Cited by 734
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
The interplay of neurotransmitters in Alzheimer's disease
Francis, P. T. (2005) · CNS Spectrums · doi:10.1017/s1092852900014164 · Cited by 302 · cited 2×
“As a result of this event, alteration of neurotransmitter (Reinikainen et al., 1990; Francis, 2005), as well as synapse and neuronal loss in the hippocampus and the neocortex (Dheen et al.”
BackgroundAging and Alzheimer's disease: comparison and associations from molecular to system level
Xia, X., Jiang, Q., McDermott, J., & Han, J. J. (2018) · Aging Cell · doi:10.1111/acel.12802 · Cited by 301 · cited 1×
“Downregulation of the Neuroinflammatory Signaling Neuroinflammation is mainly facilitated by microglia, shows a vital role in aging and neurodegeneration (Xia et al., 2018; Uddin et al., 2019d).”
BackgroundCerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299 · cited 1×
“Although AD and CVD are not the same, it is often supposed that CVD coexists with AD (Love and Miners, 2016).”
BackgroundA Dynamic Relationship between Intracellular and Extracellular Pools of Aβ
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., & LaFerla, F. M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050593 · Cited by 261
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
Self-citationValles, S. L., Dolz-Gaiton, P., Gambini, J., Borras, C., LLoret, A., Pallardo, F. V., & Viña, J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.044 · Cited by 186
Isoflavonoids — an overview of their biological activities and potential health benefits
Miadoková, E. (2009) · Interdisciplinary Toxicology · doi:10.2478/v10102-009-0021-3 · Cited by 154 · cited 1×
“Genistein (4′,5,7-trihydroxyisoflavone) is a soy-derived isoflavone and phytoestrogen (Miadoková, 2009) as shown in Figure 1.”
BackgroundZhou, X., Yuan, L., Zhao, X., Hou, C., Ma, W., Yu, H., & Xiao, R. (2014) · Nutrition · doi:10.1016/j.nut.2013.06.006 · Cited by 89 · cited 1×
“In addition, it has been revealed in another study that via reduction of the expression of inflammatory mediators, for instance, iNOS and IL-1β; genistein (50 µM) can protect the BV-1 microglial cells against the Aβ25−35-induced inflammatory response (Zhou et al., 2014).”
Background
Cited by
Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects
Rahman, M. M., Rahaman, M. S., Islam, M. R., Rahman, F., Mithi, F. M., Alqahtani, T., Almikhlafi, M. A., Alghamdi, S. Q., Alruwaili, A. S., Hossain, M. S., et al. (2021) · Molecules · doi:10.3390/molecules27010233 · Cited by 852
Self-citationKim, I.-S. (2021) · Antioxidants · doi:10.3390/antiox10071064 · Cited by 324
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Self-citationEmerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders
Uddin, M. S., Mamun, A. A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M. A., Mathew, B., Abdel-Daim, M. M., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135624 · Cited by 154
Self-citationFermented Soy Products: Beneficial Potential in Neurodegenerative Diseases
Jang, C. H., Oh, J., Lim, J. S., Kim, H. J., & Kim, J.-S. (2021) · Foods · doi:10.3390/foods10030636 · Cited by 100
Metadata
- Authors
- Uddin, M. S., & Kabir, M. T.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-20
- Volume
- 7
- Pages
- 197-197
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W2971424763
- Cited by
- 119
- References
- 15
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.